ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.
The ISCOMATRIX adjuvant has antigen-delivery and -presentation properties, as well as immunomodulatory capabilities that combine to provide enhanced and accelerated immune responses. The responses are broad, including a range of subclasses of antibodies as well as both CD4+ and CD8+ T cells. A range of ISCOMATRIX vaccines (ISCOMATRIX adjuvant combined with antigen) have been evaluated in clinical trials. The results of these completed and ongoing studies indicate that the ISCOMATRIX adjuvant is safe and generally well tolerated and increases the vaccine immune responses.
Drane
Debbie
D
CSL Limited, 45 Poplar Road, Parkville, 3052 Victoria, Australia. debbie.drane@csl.com.au
Gittleson
Charmaine
C
Boyle
Jeff
J
Maraskovsky
Eugene
E
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000277:Adjuvants, Pharmaceutic / Q000008:administration & dosage; D000818:Animals; D002784:Cholesterol / Q000008:administration & dosage* / Q000276:immunology; D002986:Clinical Trials as Topic / Q000379:methods; D004338:Drug Combinations; D006801:Humans; D010743:Phospholipids / Q000008:administration & dosage* / Q000276:immunology; D012503:Saponins / Q000008:administration & dosage* / Q000276:immunology; D014612:Vaccines / Q000008:administration & dosage* / Q000276:immunology
D000276:Adjuvants, Immunologic; D000277:Adjuvants, Pharmaceutic; D004338:Drug Combinations; C493786:ISCOMATRIX; D010743:Phospholipids; D012503:Saponins; D014612:Vaccines; D002784:Cholesterol